Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy.

Trial Profile

Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Colorectal cancer vaccine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jun 2012 Actual end date (Dec 2011) added as reported by University Hospital Medical Information Network - Japan record.
    • 09 Jun 2012 Status changed from suspended to completed as reported by University Hospital Medical Information Network - Japan record.
    • 09 Dec 2011 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top